| Company type | Public (S.A.) |
|---|---|
| Euronext Paris: TNG | |
| Industry | |
| Founded | December 1979 |
| Founders |
|
| Headquarters | , |
Key people | Dr Alessandro Riva (President and CEO as of 2023) |
| Website | www.transgene.fr |
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene’s portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris[1].
- ^ "TRANSGENE € 0,702 | Euronext Live cours de bourse". live.euronext.com. Retrieved 2024-12-22.